NDNaira Santos D'AGostini

Naira Santos D'AGostini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naira Santos D'AGostini has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Breast Cancer–Specific Survival and Prognostic Factors in a Statewide Oncology Network in Brazil: A Registry‐Linked Retrospective Cohort Study

    by Raphael Manhães Pessanha, Wesley Rocha Grippa, Luiz Cláudio Barreto Silva Neto, Naira Santos D'AGostini, Luís Carlos Lopes‐Júnior

    Background: Breast cancer survival varies widely across middle‐income settings and may be influenced by clinical stage at diagnosis and access pathways within oncology care networks. In Brazil, evidence from statewide cohorts using linked registry and mortality data remains limited. Aim: To investigate the association between clinical factors and breast cancer–specific survival among women treated in all hospitals comprising the Oncology Care Network of a state in Southeastern Brazil. Methods and Results: A retrospective cohort study was conducted using data from the Hospital Cancer Registry linked to the state Mortality Information System. Women aged ≥ 18 years diagnosed with primary breast cancer (ICD‐10: C50.x) between 2000 and 2016 were included and followed until December 31, 2021. Five‐year breast cancer–specific survival was estimated using the Kaplan–Meier method, and factors associated with mortality were assessed using cause‐specific Cox proportional hazards models with complete‐case analysis. A total of 12,096 women were included, of whom 7,191 had complete data for multivariable analysis. The mean age at diagnosis was 54.7 years. Five‐year breast cancer–specific survival ranged from 97% (95% CI: 96−97%) in stage I to 32% (95% CI: 31−37%) in stage IV. Women referred from the private healthcare system had a significantly lower risk of breast cancer mortality than those referred from the public system (HR: 0.83; 95% CI: 0.75−0.93; p = 0.001). Advanced clinical stage remained the strongest predictor of mortality, and the presence of distant metastasis at diagnosis increased the risk of breast cancer death by 49% (HR: 1.49; 95% CI: 1.14−1.94; p = 0.003). Conclusion: Breast cancer–specific survival in Espírito Santo is strongly determined by stage at diagnosis and by differential access pathways within the oncology care network. Strengthening early diagnostic strategies, improving referral coordination, and ensuring equitable access to timely treatment are essential to reduce survival disparities in this setting.


  • Open Access

    Cardiotoxicidad inducida por quimioterapia en pacientes con cáncer: estudio observacional en un hospital de referencia oncológica en el sudeste de Brasil

    by Karoline Neumann, Karolini Zuqui Nunes, Wesley Rocha Grippa, Naira Santos D’aGostini, Sara Isabel Pimentel de Carvalho Schuab, Luís Carlos Lopes-Júnior

    Objetivo: evaluar el perfil clínico, inflamatorio y electrocardiográfico de pacientes con cáncer en la fase pre-quimioterapia, con el objetivo de identificar tempranamente signos indicativos de toxicidad cardiovascular. Método: estudio observacional, transversal, realizado entre noviembre de 2022 y diciembre de 2023, con adultos con cáncer en estadios I a III, tratados en un hospital del sudeste de Brasil. Se recolectaron datos sociodemográficos, clínicos y tumorales, además de pruebas de laboratorio y electrocardiográficas realizadas antes de la primera infusión de quimioterapia. Se realizaron análisis descriptivos utilizando el software R. Resultados: participaron 84 pacientes, la mayoría mujeres (72,6%) con diagnóstico de cáncer de mama (57,1%). Hubo una prevalencia de inflamación sistémica, con proteína C reactiva elevada en 35,7%, una relación neutrófilos-linfocitos aumentada en 23,5% y una relación plaquetas-linfocitos en 27,2%. Se observó una asociación significativa entre el índice de masa corporal elevado y las alteraciones de la onda T (p=0,005). Aunque 10 pacientes presentaron un intervalo QT corregido prolongado, no se identificaron otras asociaciones estadísticamente significativas. Conclusión: la fase pre-quimioterapia reveló alteraciones inflamatorias y electrocardiográficas relevantes, incluso en ausencia de cardiotoxicidad establecida. Estos hallazgos refuerzan la importancia de la evaluación cardiovascular basal y la monitorización multidisciplinaria en cardiología oncológica, especialmente en pacientes con factores de riesgo modificables. Se recomiendan estudios longitudinales para dilucidar las trayectorias clínicas y pronósticas de estas alteraciones.

  • Open Access

    Cardiotoxicidade induzida por quimioterápicos em pacientes com câncer: estudo observacional em hospital de referência oncológica no Sudeste do Brasil

    by Karoline Neumann, Karolini Zuqui Nunes, Wesley Rocha Grippa, Naira Santos D’aGostini, Sara Isabel Pimentel de Carvalho Schuab, Luís Carlos Lopes-Júnior

    Objetivo: avaliar o perfil clínico, inflamatório e eletrocardiográfico de pacientes oncológicos na fase pré-quimioterapia, visando à identificação precoce de sinais indicativos de toxicidade cardiovascular. Método: estudo observacional, transversal, realizado entre novembro de 2022 e dezembro de 2023, com adultos com câncer em estágios I a III, atendidos em um hospital do Sudeste brasileiro. Foram coletados dados sociodemográficos, clínicos e tumorais, além de exames laboratoriais e eletrocardiográficos realizados antes da primeira infusão quimioterápica. Análises descritivas foram conduzidas no software R. Resultados: participaram 84 pacientes, sendo a maioria mulheres (72,6%) com diagnóstico de câncer de mama (57,1%). Verificou-se prevalência de inflamação sistêmica, com proteína C-reativa elevada em 35,7%, razão neutrófilo-linfócito aumentada em 23,5% e razão plaqueta-linfócito em 27,2%. Observou-se associação significativa entre índice de massa corporal elevado e alterações na onda T (p=0,005). Embora 10 pacientes apresentassem intervalo QT corrigido prolongado, não foram identificadas outras associações estatisticamente significativas. Conclusão: a fase pré-quimioterapia revelou alterações inflamatórias e eletrocardiográficas relevantes, mesmo na ausência de cardiotoxicidade estabelecida. Os achados reforçam a importância da avaliação cardiovascular basal e do acompanhamento multiprofissional na cardio-oncologia, especialmente em pacientes com fatores de risco modificáveis. Estudos longitudinais são recomendados para elucidar as trajetórias clínicas e prognósticas dessas alterações.

  • Open Access

    Chemotherapy-induced cardiotoxicity in cancer patients: an observational study at an Oncology reference hospital from southeastern Brazil

    by Karoline Neumann, Karolini Zuqui Nunes, Wesley Rocha Grippa, Naira Santos D’aGostini, Sara Isabel Pimentel de Carvalho Schuab, Luís Carlos Lopes-Júnior

    Objective: to assess the clinical, inflammatory and electrocardiographic profile of cancer patients undergoing the Pre-chemotherapy phase, with the purpose of early identifying cardiovascular toxicity indicative signs. Method: an observational and cross-sectional study, conducted between November2022 and December2023 with adult cancer patients in stagesI toIII treated at a hospital from southern Brazil. Sociodemographic, clinical and tumor-related data were collected, in addition to laboratory and electrocardiographic tests performed before the first chemotherapy infusion. Descriptive analyses were carried out in the Rsoftware. Results: the participants were 84 patients, mostly women (72.6%) with breast cancer diagnoses(57.1%). Prevalence of systemic inflammation was verified, with high C-reactive protein in 35.7% and increased neutrophil-lymphocyte and platelet-lymphocyte ratios in 23.5% and 27.2%, respectively. A significant association was observed between high Body Mass Index and T-wave alterations (p=0.005). Although 10 patients presented prolonged corrected QT intervals, no other statistically significant associations were identified. Conclusion: the pre-chemotherapy phase revealed relevant inflammatory and electrocardiographic alterations, even in the absence of installed cardiotoxicity. The findings reinforce the importance of baseline cardiovascular evaluations and of multi-professional follow-up in Cardio-Oncology, especially for patients with modifiable risk factors. Longitudinal studies are recommended to elucidate the clinical and prognostic evolution of these alterations.

  • Open Access

    Health-Related Quality of Life in Newly Diagnosed Cancer Patients Prior to First Outpatient Chemotherapy: A Cross-Sectional Study

    by Etreo Junior Carneiro da Silva Minarini, Raphael Manhães Pessanha, Sara Isabel Pimentel de Carvalho Schuab, Naira Santos D’aGostini, Victoria Oliveira Santos, Jonathan Grassi, Wesley Rocha Grippa, Karolini Zuqui Nunes, Luís Carlos Lopes-Júnior

    Introduction: Cancer imposes substantial physical and psychological burdens that negatively affect patients’ health-related quality of life (HRQoL). Assessing HRQoL prior to chemotherapy initiation is essential for tailoring early supportive care strategies. Objective: To describe the characteristics and identify the factors associated with HRQoL in newly diagnosed cancer patients immediately before initiating outpatient chemotherapy. Method: This cross-sectional study included adults with newly diagnosed stage I–III cancer scheduled to begin outpatient chemotherapy at a Brazilian cancer referral center. Sociodemographic and tumor-related data were obtained using a structured questionnaire. HRQoL was assessed with the EQ-5D-3L instrument. Descriptive and bivariate analyses were performed using Fisher's exact test. Results: Eighty-four patients were included (mean age: 57.68 years); most were female (72.62%), of mixed ethnicity (40.48%), had completed only primary education (48.81%), and were married (51.19%). The average time from diagnosis to treatment initiation was 120 days, and 60.71% reported comorbidities. Breast cancer was the most common diagnosis (57.14%), predominantly at Stage II (57.14%). The mean EQ-5D-3L index score was 77.79. Comorbidities were significantly associated with impaired mobility ( p = .009), and female patients reported significantly more anxiety and depression than males ( p = .005). Inflammatory markers revealed that most patients had low neutrophil-to-lymphocyte ratio (76.54%), low platelet-to-lymphocyte ratio (72.84%), and elevated C-reactive protein (CRP; 84.52%). In the multivariate analysis, the presence of comorbidities remained significantly associated with worse mobility (OR = 5.456; 95% CI [1.205–24.707]; p = .028), and male sex was independently associated with lower levels of anxiety and depression (OR = 0.206; [0.067–0.634]; p = .006). A nonsignificant trend was also observed between higher CRP levels and increased pain (OR = 2.800; [0.824–9.510]; p = .099). Conclusions: Patients with newly diagnosed cancer experience impaired HRQoL even before starting chemotherapy. Comorbidities were associated with worse mobility, and female patients reported higher levels of anxiety and depression. These findings support the need for early multidisciplinary care to mitigate functional and emotional burdens prior to treatment.


  • Open Access

    Cluster de sintomas oncológicos em mulheres com neoplasia maligna de mama não metastático hospitalizadas

    by Roberto Júnio Gomes Silva, Wesley Rocha Grippa, Raphael Manhães Pessanha, Júlia Anhoque Cavalcanti Marcarini, Luiz Cláudio Barreto Silva Neto, Naira Santos D’aGostini, Luís Carlos Lopes-Júnior

    Objetivos: descrever e analisar os sintomas oncológicos mais prevalentes, bem como sua intensidade, incômodo e clusterização em mulheres com neoplasia maligna da mama não metastático hospitalizadas.


  • Open Access

    Cancer symptom cluster in hospitalized women with breast cancer: a descriptive observational study

    by Roberto Júnio Gomes Silva, Wesley Rocha Grippa, Raphael Manhães Pessanha, Júlia Anhoque Cavalcanti Marcarini, Luiz Cláudio Barreto Silva Neto, Naira Santos D’aGostini, Luís Carlos Lopes-Júnior

    Objectives: to describe and analyze the most prevalent cancer symptom clusters as well as their intensity, discomfort and clustering in hospitalized women with non-metastatic malignant breast cancer.


  • Open Access

    Perfil clínico-epidemiológico de pacientes com câncer sob quimioterapia ambulatorial

    by Raphael Manhães Pessanha, Naira Santos D’aGostini, Lívia Machado Giacomin, Luana Santos Busatto, Mariana Cremasco Amaral, Anna Clara Silva Victor De Souza, Wesley Rocha Grippa, Luis Carlos Lopes-Júnior

    Objetivo: Descrever o perfil clínico-epidemiológico de pacientes com câncer indicados para quimioterapia ambulatorial. Método: Estudo observacional descritivo realizado com pacientes oncológicos encaminhados para quimioterapia ambulatorial em um hospital de referência no tratamento do câncer no Sudeste do Brasil. As informações sociodemográficas, clínicas e relacionadas às características dos tumores foram obtidas por meio de questionário e consulta aos prontuários médicos. Realizou-se análise estatística descritiva dos dados. Resultados: Foram analisados 84 pacientes, dos quais a maioria era composta por mulheres (72,62%). A faixa etária predominante foi de 50 a 64 anos (42,86%). A maioria dos pacientes se declarou de cor parda (40,48%), tinha renda mensal de um salário mínimo (45,24%), ensino fundamental completo (48,81%) e era casada (51,19%). A maior parte não possuía plano de saúde (82,14%). A neoplasia maligna da mama foi a mais comum, frequentemente diagnosticada no estágio II (57,14%). A quimioterapia foi o tratamento predominante (57,14%). Conclusão: O perfil sociodemográfico e clínico identificado neste estudo evidenciou a complexidade multifatorial, histológica e hematológica associada ao câncer. Para um melhor prognóstico, é fundamental avaliar variáveis sociodemográficas e clínicas, além de monitorar biomarcadores inflamatórios por meio do hemograma durante os ciclos de quimioterapia, garantindo um acompanhamento mais eficaz desses pacientes.